July 01, 2022
Article
Here is a rundown of the most popular and significant stories we covered this past week.
June 30, 2022
Antibody levels decline in individuals with hybrid immunity similarly to vaccinated individuals, meaning all people need a booster vaccine to protect against future, potentially severe, infection.
A computational framework for estimating vaccine effectiveness based on genetic differences of SARS-CoV-2 variants showed promising results in a new study that verified the model with clinical trial data.
June 28, 2022
After an all-day meeting, the FDA’s Vaccine and Related Biological Products Advisory Committee (VRBPAC) voted 90% YES to recommend this fall’s COVID-19 booster doses target Omicron.
June 27, 2022
Sanofi and GSK, Pfizer-BioNTech, and Moderna are all working on booster candidates specifically designed to neutralize Omicron and its subvariants.
June 26, 2022
Rochelle P. Walensky, MD, MPH, signs off on the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices’ (ACIP) recommendation for individuals 6 through 17 years of age.
June 20, 2022
Patients with a history of infection who were also vaccinated had the strongest protection, the data showed.
June 19, 2022
Studies, advances, and authorizations continue in this paramount area within infectious disease.
The CDC director endorsed the vote, and vaccines could be available to this young pediatric population by later this week.
June 17, 2022
This past week has been extremely busy in infectious disease with a lot of vaccine news that could impact young children. In addition, GSK reported on its phase 3 study on its RSV vaccine for seniors.
Monkeypox Symptoms in London Patients Differ from Prior Outbreaks
How COVID-19 Infiltrates and Inflames the Heart
Top 5 Infectious Disease Stories of the Week: July 1, 2022
Communities With More Racial Prejudice Have Worse Health Outcomes
